ALLMedicine™ Amyotrophic Lateral Sclerosis Center

Jul 30th, 2021 - Perampanel, a selective non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonist, is capable of slowing the progression of the amyotrophic lateral sclerosis (ALS) phenotype and increasing the number of anterior horn c...

Jul 29th, 2021 - Development of effective treatment for amyotrophic lateral sclerosis (ALS) has been hampered by disease heterogeneity, a limited understanding of underlying pathophysiology and methodological design challenges. Here we have evaluated two major the...

Jul 28th, 2021 - We aimed to develop a model to predict amyotrophic lateral sclerosis (ALS) disease progression based on clinical and neuromuscular ultrasound (NMUS) parameters. ALS patients were prospectively recruited. Muscle fasciculation (≥2 over 30-seconds, e...

Jul 28th, 2021 - To investigate whether GSTA1, GSTO2, and GSTZ1 are relevant to an increased risk of amyotrophic lateral sclerosis (ALS) in a Chinese population. In this study, 143 sporadic ALS (sALS) patients (83 men, 60 women) and 210 age- and sex-matched health...

Jul 28th, 2021 - The majority of radiology studies in neurodegenerative conditions infer group-level imaging traits from group comparisons. While this strategy is helpful to define phenotype-specific imaging signatures for academic use, the meaningful interpretati...

Jan 9th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...

Dec 25th, 2017 - Neurological diseases are frequently associated with swallowing disorders and malnutrition. Moreover, patients with neurological diseases are at increased risk of micronutrient deficiency and dehydration. On the other hand, nutritional factors may...

May 27th, 2010 - These EFNS guidelines on the molecular diagnosis of motoneuron disorders, neuropathies and myopathies are designed to summarize the possibilities and limitations of molecular genetic techniques and to provide diagnostic criteria for deciding when ...

Oct 14th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...

May 5th, 2020 - The Goal of the Proposed Study is to perform an open label, 60 subject, Phase II multi-site clinical trial to investigate the safety and efficacy of intrathecal treatment of aaMSCs in ALS. Patients will be treated with 1 x 10^8 aaMSCs every 3 mont...

May 1st, 2020 - Objective: In this Phase I, proof-of-concept study, we aim to determine whether an antiretroviral regimen approved to treat human immunodeficiency virus (HIV) infection would also suppress levels of Human Endogenous Retrovirus-K (HERV-K) found to ...

Apr 22nd, 2020 - This is a randomised, double-blind, placebo controlled study on a cannabis-based medicine extract (MediCabilis CBD Oil), in patients with Amyotrophic Lateral Sclerosis or Motor Neurone Disease. Participants will be randomised in a 1:1 ratio to rec...

Apr 15th, 2020 - Amyotrophic Lateral Sclerosis (ALS) is an incurable disease of unknown etiology that in a short time leads to significant impairment of motor functions and death. The frequency of ALS is 4-8/100 000. Mostly it affects people between 40 and 70 year...

Apr 14th, 2020 - Objectives The primary objective is to evaluate patients referred with a diagnosis of frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), or related adult-onset neurodegenerative disorder to assess patient eligibility for ongoing p...

Jun 14th, 2021 - This transcript has been edited for clarity. Hello. This is Paul Auwaerter for Medscape Infectious Diseases, speaking from Johns Hopkins University School of Medicine. Spring is in full swing and tick season has certainly returned. I thought I wou...

Jun 7th, 2021 - (Reuters Health) - Scientists have identified four specific, dominant variants of the SPTLC1 gene in 11 children from seven different families who appear to have a new and unique form of amyotrophic lateral sclerosis (ALS). The findings suggest th...

Apr 20th, 2021 - Blue-collar workers, particularly carpenters and construction workers, have a significantly increased risk for amyotrophic lateral sclerosis (ALS) compared with white-collar workers, new research shows. Investigators found manual laborers had a tw...

Mar 15th, 2021 - "Symptoms, then, are in reality nothing but a cry from suffering organs" – Jean-Martin Charcot Nearly 130 years after his death, Jean-Martin Charcot's name still resonates with modern neurologists. The famed 19th century French physician made myri...

Mar 11th, 2021 - NEW YORK (Reuters Health) - A new compound, NU-9, improved diseased upper motor neurons (UMN) in mice and shows promise for treating amyotrophic lateral sclerosis (ALS) in humans, though more work is needed before a clinical trial can be started, ...